Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel
NASDAQ:TNYA

Tenaya Therapeutics Q3 2026 Earnings Date & Estimates

Tenaya Therapeutics logo
$0.38 -0.03 (-6.78%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.87%)
As of 10/16/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenaya Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Tenaya Therapeutics in Q3 2026

Tenaya Therapeutics is expected to post earnings of -$0.10 per share on revenue of $0.80 million. In the same quarter a year earlier Tenaya Therapeutics reported -$0.12 per share. Tenaya Therapeutics last reported on August 5, 2026, posting -$0.20 per share and missing the -$0.0683 consensus estimate. Tenaya Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.10
Expected Revenue
$0.80 million
Prior-Year EPS
-$0.12

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.20 (Missed by -$0.1317)
Last Quarter Revenue
$1.11 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Tenaya Therapeutics Q3 2026 Earnings FAQ

Tenaya Therapeutics (NASDAQ:TNYA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Tenaya Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Tenaya Therapeutics to post earnings of -$0.10 per share for Q3 2026.

The consensus revenue estimate for Tenaya Therapeutics is $0.80 million for Q3 2026.

Tenaya Therapeutics Earnings Headlines

Tenaya Therapeutics (NASDAQ:TNYA) and Sutro Biopharma (NASDAQ:STRO) Critical Contrast
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31113535
Tenaya Therapeutics Announces RMAT Designation To TN-401
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690729/tenaya-therapeutics-announces-rmat-designation-to-tn-401.aspx
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690766/tenaya-s-tn-401-receives-fda-rmat-status-for-pkp2-associated-cardiomyopathy-stock-up.aspx
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tenaya-therapeutics-granted-u-fda-123000453.html
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361082/0/en/tenaya-therapeutics-granted-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-tn-401-for-the-treatment-of-pkp2-associated-arrhythmogenic-right-ventricular-cardiom.html
See More Tenaya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email.

About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ:TNYA) (NASDAQ:TNYA) is a biotechnology company focused on developing therapies for cardiovascular diseases. The company uses a combination of gene therapy, cell therapy, and precision medicine approaches to address the genetic and biological causes of heart disease, including conditions for which treatment options remain limited.

Tenaya’s research and development programs have included therapies designed to replace or correct disease-associated genes and restore the function of cardiac muscle cells. Its pipeline has included TN-201, an investigational gene therapy for hypertrophic cardiomyopathy associated with MYBPC3 mutations, and TN-401, an investigational gene therapy being developed for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations. The company has also pursued discovery programs involving gene editing, induced pluripotent stem cell-derived cardiomyocytes, and small-molecule medicines.

Founded in 2016 and headquartered in South San Francisco, California, Tenaya conducts research and development activities primarily in the United States while seeking to advance potential treatments for patients with inherited and other serious cardiovascular disorders. The company is led by Chief Executive Officer Faraz Ali.

View Tenaya Therapeutics Profile
Earnings Tools